<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711436074</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711436074</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Turkish Perspective on Coronary Artery Bypass Surgery and Percutaneous Coronary Artery Intervention in Chronic Heart Failure Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kozdağ</surname>
<given-names>Güliz</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ertaş</surname>
<given-names>Gökhan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711436074">2</xref>
<xref ref-type="corresp" rid="corresp1-0003319711436074"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emre</surname>
<given-names>Ender</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yaymaci</surname>
<given-names>Mehmet</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319711436074">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Celikyurt</surname>
<given-names>Umut</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kahraman</surname>
<given-names>Göksel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yılmaz</surname>
<given-names>İrem</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuruüzüm</surname>
<given-names>Kurtuluş</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ural</surname>
<given-names>Dilek</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711436074">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711436074"><label>1</label>Department of Cardiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey</aff>
<aff id="aff2-0003319711436074"><label>2</label>Department of Cardiology, Faculty of Medicine, Bezmialem Vakif University, İstanbul, Turkey</aff>
<aff id="aff3-0003319711436074"><label>3</label>Department of Cardiology, Kütahya Government Hospital, Kütahya, Turkey</aff>
<author-notes>
<corresp id="corresp1-0003319711436074">Gökhan Ertaş, Department of Cardiology, Bezmialem Vakif University Faculty of Medicine, Adnan Menderes Bulvarı Vatan Caddesi, 34093 Fatih/İstanbul, Turkey Email: <email>drgokhanertas@yahoo.com.tr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>125</fpage>
<lpage>130</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The impact of coronary revascularization methods (coronary artery bypass graft [CABG] surgery and stent implantation) on clinical outcome has not been determined yet in patients with systolic heart failure (SHF). We examined outcomes in patients discharged from our hospital after hospitalization for decompensated SHF. Of 637 patients with SHF (mean age, 64 ± 13 years; mean ejection fraction, 26.5% ± 9%), 402 patients (63%) had coronary artery disease (CAD) and 235 patients (37%) had no CAD; 223 patients (35%) died because of cardiovascular reasons during follow-up. Patients who had stenting alone and patients who had CABG surgery and stenting had better prognosis than patients with CAD but no revascularization procedure (<italic>P</italic> &lt; .001 and <italic>P</italic> = .013, respectively). In the patients with SHF having CAD who had stenting and CABG surgery + stenting may have better prognosis compared with patients with CAD who had no revascularization procedure in their past.</p>
</abstract>
<kwd-group>
<kwd>coronary revascularization</kwd>
<kwd>coronary artery bypass graft surgery</kwd>
<kwd>stent implantation</kwd>
<kwd>chronic heart failure</kwd>
<kwd>coronary artery disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711436074">
<title>Introduction</title>
<p>Systolic heart failure, also termed as heart failure (HF) with reduced ejection fraction, is one of the most common clinical subsets of chronic heart failure (CHF). During past 3 decades, there have been considerable advances in the management of CHF. With their implementation, a substantial improvement in the prognosis of patients with CHF has been observed. Although it has been reported that with modern pharmacotherapy, the annualized mortality rate has decreased,<sup>
<xref ref-type="bibr" rid="bibr1-0003319711436074">1</xref>
</sup> the mortality rate was still higher in patients with HF. Ahmed et al reported that all-cause mortality occurred in 36% during 4 years of follow-up.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436074">2</xref>
</sup>
</p>
<p>Coronary artery disease (CAD) is a major risk factor for CHF.<sup>
<xref ref-type="bibr" rid="bibr3-0003319711436074">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319711436074">4</xref>
</sup> Damage from ongoing myocardial ischemia may adversely affect disease progression and prognosis in CHF.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711436074">4</xref>
<xref ref-type="bibr" rid="bibr5-0003319711436074"/>
<xref ref-type="bibr" rid="bibr6-0003319711436074"/>
<xref ref-type="bibr" rid="bibr7-0003319711436074"/>–<xref ref-type="bibr" rid="bibr8-0003319711436074">8</xref>
</sup> Revascularization with coronary artery bypass graft (CABG) surgery improves left ventricular regional and global mechanical and metabolic function.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711436074">1</xref>
</sup> Several studies have also demonstrated that reperfusion treatment either by CABG surgery or by percutaneous coronary intervention (PCI) improves left ventricular function.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436074">9</xref>,<xref ref-type="bibr" rid="bibr10-0003319711436074">10</xref>
</sup> Successful revascularization has the potential to produce beneficial effects on left ventricular remodeling.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436074">9</xref>
<xref ref-type="bibr" rid="bibr10-0003319711436074"/>–<xref ref-type="bibr" rid="bibr11-0003319711436074">11</xref>
</sup> Coronary revascularization methods have changed the clinical prognosis related to coronary artery disease (CAD).<sup>
<xref ref-type="bibr" rid="bibr12-0003319711436074">12</xref>
<xref ref-type="bibr" rid="bibr13-0003319711436074"/>
<xref ref-type="bibr" rid="bibr14-0003319711436074"/>–<xref ref-type="bibr" rid="bibr15-0003319711436074">15</xref>
</sup> For patients with CHF who have systolic dysfunction, however, the impact of both CABG surgery and percutaneous revascularization procedures on clinical outcome is yet to be determined.</p>
</sec>
<sec id="section2-0003319711436074" sec-type="methods">
<title>Methods</title>
<sec id="section3-0003319711436074">
<title>Patient Selection</title>
<p>In this prospective observational study, we evaluated the outcomes (cardiac mortality) in patients discharged from the wards of the Cardiology Clinic of Medical School of Kocaeli University between January 2003 and December 2009 after hospitalization for chronic decompensated HF. A total of 637 patients with HF (409 male, 228 female, mean age, 64 ± 13 years; mean ejection fraction, 26.5% ± 11.0%) were recruited. Etiology of the dilated cardiomyopathy had been investigated by coronary angiography in all patients; 402 (63%) patients had CAD and 235 (37%) patients had no CAD (<xref ref-type="table" rid="table1-0003319711436074">Table 1</xref>).</p>
<table-wrap id="table1-0003319711436074" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical Characteristics of the Patients With Chronic Heart Failure</p>
</caption>
<graphic alternate-form-of="table1-0003319711436074" xlink:href="10.1177_0003319711436074-table1.tif"/>
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patient (n = 637)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64 ± 13</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td align="center">409/228</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td align="center">124/76</td>
</tr>
<tr>
<td>Ischemic cardiomyopathy</td>
<td>402 (63%)</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>463 (73%)</td>
</tr>
<tr>
<td>History of diabetes</td>
<td>223 (35%)</td>
</tr>
<tr>
<td>History of CABG surgery</td>
<td>107 (17%)</td>
</tr>
<tr>
<td>History of stent implantation </td>
<td>96 (15%)</td>
</tr>
<tr>
<td>History of CABG surgery + stent implantation</td>
<td>24 (4%)</td>
</tr>
<tr>
<td>History of smoking</td>
<td>206 (32%)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>167 (26%)</td>
</tr>
<tr>
<td colspan="2">Medication</td>
</tr>
<tr>
<td>β-Blockers</td>
<td>443 (70%)</td>
</tr>
<tr>
<td>Nitrates</td>
<td>258 (41%)</td>
</tr>
<tr>
<td>ACE-I/ARB</td>
<td>522 (82%)</td>
</tr>
<tr>
<td>Furosemid</td>
<td>513 (81%)</td>
</tr>
<tr>
<td>Statin</td>
<td>381 (60%)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>564 (89%)</td>
</tr>
<tr>
<td colspan="2">Clinical parameters</td>
</tr>
<tr>
<td>Left ventricular ejection fraction, %</td>
<td>26.5 ± 11.0</td>
</tr>
<tr>
<td>Hemoglobin, mg/dL</td>
<td>12.6 ± 11.3</td>
</tr>
<tr>
<td>hs-CRP, mg/dL</td>
<td>45 ± 6</td>
</tr>
<tr>
<td>BNP, pg/mL</td>
<td>45 ± 6</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.6 ± 1.2</td>
</tr>
<tr>
<td>Homosistein, mg/dL</td>
<td>18 ± 8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711436074">
<p>Abbreviations: ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; hs-CRP, high-sensitive C-reactive protein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In all patients, left ventricular enlargement (end-diastolic diameter &gt;56 mm) and systolic dysfunction (ejection fraction &lt;45%) were documented by 2-dimensional and M-mode echocardiography. Paclitaxel-eluting stents and bare metal stents were implanted.</p>
</sec>
<sec id="section4-0003319711436074">
<title>Study Approval</title>
<p>The study was conducted in accordance with the Declaration of Helsinki. Study protocol was approved by the local ethics committee and individuals gave their informed consent prior to study entry.</p>
</sec>
<sec id="section5-0003319711436074">
<title>Echocardiography</title>
<p>All participants underwent transthoracic echocardiography by means of an echocardiograph equipped with a broadband transducer (Vivid 7; GE VingMed Ultrasound AS, Horten, Norway). Measurements of the left atrium and left and right ventricles were obtained from parasternal long-axis view as recommended by the American Society of Echocardiography.<sup>
<xref ref-type="bibr" rid="bibr16-0003319711436074">16</xref>
</sup> Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson rule in the apical 2- and 4-chamber views.</p>
</sec>
<sec id="section6-0003319711436074">
<title>Blood Samples</title>
<p>Fasting blood samples were drawn from a large antecubital vein in each patient for determination of biochemical and hemostatic parameters during the first 3 days of hospitalization. Levels of brain natriuretic peptide (BNP) were measured using commercially available Triage BNP test (Biosite Incorporated, San Diego, California), which is a fluorescence immunoassay for the quantification of BNP. Serum high-sensitive C-reactive protein (hsCRP) was measured using a sensitive nephelometric assay (Image 800 Immunochemistry System; Beckman Coulter, Los Angeles). Sedimentation, albumin, creatinine, hemoglobin, and lipid levels were measured by standard methods.</p>
</sec>
<sec id="section7-0003319711436074">
<title>Patient Follow-Up</title>
<p>Follow-up was started on the first day of hospitalization. Clinical follow-up was done by phone contact and examination of patients in the outpatient clinic. All patients were followed for a mean duration of 38 ± 15 months (3-82 months). The primary end point of the study was cardiac death including sudden death and death attributable to advanced HF.</p>
</sec>
<sec id="section8-0003319711436074">
<title>Statistical Methods</title>
<p>The SPSS 13.0 (SPSS Inc, an IBM company; Chicago, Illinois) package was used for statistical analyses. Results are presented as mean ± standard deviation or as percentages and numbers for categorical data. In comparing patients with cardiac death and without cardiac death, continuous variables that were normally distributed were analyzed with the 2-tailed <italic>t</italic> test, and unequally distributed variables were analyzed with the Mann-Whitney <italic>U</italic> test. Categorical data and proportions were analyzed using the χ<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436074">2</xref>
</sup> or Fisher exact test where appropriate.</p>
<p>To compare the values between and within the patients with CAD but those without coronary artery revascularization, patients without CAD, patients with CABG surgery, patients with stent implantation, and patients with both CABG surgery and stent implantation, a 1-way analysis of variance was used. Homogeneity of variances was tested for all variables with Levene test. If equal variances were assumed, Tukey honestly significant difference (HSD) post hoc test was applied; if not, the Tamhane T2 test was used to compare the parameters within groups. The Bonferroni correction was used to determine statistically significant values among patient groups with various types of treatments of CHF.</p>
<p>During the follow-up period, Cox proportional hazard analysis was used to evaluate the patients with CAD but those without coronary artery revascularization, patients without CAD, patients who had CABG surgery, of patients with stent implantation, and patients with both CABG surgery and stent implantation. A <italic>P</italic> value &lt; .05, 2-sided, was considered significant.</p>
</sec>
</sec>
<sec id="section9-0003319711436074">
<title>Results</title>
<p>Of all, 223 (35%) patients died because of cardiovascular reasons during the follow-up period; 176 (28%) patients with CAD had no revascularization procedure, 107 (17%) patients had CABG surgery, 96 (15%) patients had stent implantation, and 24 (4%) patients had both CABG surgery and stent implantation. In this prospective observational study, 48% of patients with CAD but those without coronary artery revascularization, 32% of patients without CAD, 35% of patients who had CABG surgery, 23% of patients with stent implantation, and 17% patients with both CABG surgery and stent implantation died due to cardiovascular reasons during the follow-up period (<italic>P</italic> &lt; .001, between the groups; <xref ref-type="table" rid="table2-0003319711436074">Table 2</xref>). The patients who had stent implantation and patients who had CABG + stent implantation seemed to have better prognosis than those with CAD who had no revascularization procedure in their past (<italic>P</italic> &lt; .001 and <italic>P</italic> = .013, respectively). The patients without CAD had better prognosis than the patients with CAD but without coronary revascularization procedure in the past (<italic>P</italic> = .003; <xref ref-type="table" rid="table3-0003319711436074">Table 3</xref>).</p>
<table-wrap id="table2-0003319711436074" position="float">
<label>Table 2.</label>
<caption>
<p>Different Characteristics of the Patient Groups</p>
</caption>
<graphic alternate-form-of="table2-0003319711436074" xlink:href="10.1177_0003319711436074-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Patients Without CAD (n = 234)</th>
<th>Patients With CAD Had No Revascularization Procedure (n = 176)</th>
<th>Patients With Stent Implantation (n = 96)</th>
<th>Patients With CABG Surgery (n = 107)</th>
<th>Patients With CABG Surgery and Stent Implantation (n = 24)</th>
<th>
<italic>P </italic>(Within Groups)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular death</td>
<td>76 (32)</td>
<td>87 (49%)<sup>a</sup>
</td>
<td>22 (23%)<sup>b</sup>
</td>
<td>39 (36%)</td>
<td>4 (17%)<sup>c</sup>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age, years</td>
<td>61 ± 15</td>
<td>66 ± 11<sup>a</sup>
</td>
<td>62 ± 13<sup>d</sup>
</td>
<td>65 ± 9</td>
<td>68 ± 10<sup>e</sup>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td align="center">124/77</td>
<td align="center">124/77</td>
<td align="center">124/74</td>
<td align="center">126/77</td>
<td align="center">128/77</td>
<td>NS</td>
</tr>
<tr>
<td>Heart rate/minute</td>
<td>84 ± 18</td>
<td>80 ± 15</td>
<td>78 ± 15<sup>d</sup>
</td>
<td>80 ± 22</td>
<td>81 ± 17</td>
<td>.033</td>
</tr>
<tr>
<td>Body mass index, kg/m<sup>2</sup>
</td>
<td>26 ± 5</td>
<td>27 ± 5</td>
<td>27 ± 4</td>
<td>27 ± 4</td>
<td>27 ± 3</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension</td>
<td>163 (70%)</td>
<td>135 (77%)</td>
<td>60 (63%)</td>
<td>84 (79%)</td>
<td>21 (88%)</td>
<td>NS</td>
</tr>
<tr>
<td>Diabetes</td>
<td>47 (20%)</td>
<td>87 (49%)</td>
<td>33 (34%)</td>
<td>47 (44%)</td>
<td>9 (38%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Orthopnea</td>
<td>108 (46%)</td>
<td>57 (32%)<sup>a</sup>
</td>
<td>23 (24%)<sup>d</sup>
</td>
<td>43 (40%)</td>
<td>6 (25%)</td>
<td>.001</td>
</tr>
<tr>
<td>Jugular vein distension</td>
<td>141 (60%)</td>
<td>93 (53%)</td>
<td>42 (44%)<sup>d</sup>
</td>
<td>63 (59%)</td>
<td>11 (46%)</td>
<td>.053</td>
</tr>
<tr>
<td>Pretibial edema</td>
<td>168 (72%)</td>
<td>108 (61%)</td>
<td>52 (54%)<sup>f</sup>
</td>
<td>67 (63%)</td>
<td>14 (58%)</td>
<td>.025</td>
</tr>
<tr>
<td>Nitrate use</td>
<td>32 (14%)</td>
<td>93 (53%)<sup>g</sup>
</td>
<td>58 (60%)<sup>f</sup>
</td>
<td>60 (56%)<sup>h</sup>
</td>
<td>15 (63%)<sup>h</sup>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ACE-I/ARB</td>
<td>184 (79%)</td>
<td>156 (89%)</td>
<td>80 (83%)</td>
<td>86 (80%)</td>
<td>16 (67%)</td>
<td>.025</td>
</tr>
<tr>
<td>Digoxin</td>
<td>70 (30%)</td>
<td>30 (17%)<sup>a</sup>
</td>
<td>16 (17%)</td>
<td>22 (21%)</td>
<td>3 (13%)</td>
<td>.007</td>
</tr>
<tr>
<td>Statin</td>
<td>79 (34%)</td>
<td>127 (72%)<sup>g</sup>
</td>
<td>81 (84%)<sup>f</sup>
</td>
<td>73 (68%)<sup>h</sup>
</td>
<td>21 (88%)<sup>i</sup>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.3 ± 1.0</td>
<td>1.6 ± 1.0</td>
<td>1.5 ± 1.6</td>
<td>1.6 ± 1.3</td>
<td>1.2 ± 0.3</td>
<td>NS</td>
</tr>
<tr>
<td>Potassium, mg/dL</td>
<td>4.2 ± 0.6</td>
<td>4.4 ± 0.6</td>
<td>4.4 ± 0.6</td>
<td>4.4 ± 0.7</td>
<td>4.3 ± 0.7</td>
<td>.014</td>
</tr>
<tr>
<td>BNP, pg/mL</td>
<td>1213 ± 1028</td>
<td>1310 ± 1119</td>
<td>958 ± 817<sup>j</sup>
</td>
<td>1017 ± 925</td>
<td>697 ± 407<sup>c</sup>
</td>
<td>.004</td>
</tr>
<tr>
<td>hs-CRP, mg/dL</td>
<td>2.4 ± 4.9</td>
<td>3.2 ± 4.2</td>
<td>2.5 ± 3.4</td>
<td>2.5 ± 4.0</td>
<td>1.5 ± 2.3</td>
<td>NS</td>
</tr>
<tr>
<td>LDL-cholesterol, mg/dL</td>
<td>105 ± 38</td>
<td>108 ± 38</td>
<td>105 ± 33</td>
<td>101 ± 40</td>
<td>104 ± 51</td>
<td>NS</td>
</tr>
<tr>
<td>HDL-cholesterol, mg/dL</td>
<td>38 ± 12</td>
<td>35 ± 10</td>
<td>35 ± 9</td>
<td>34 ± 11<sup>k</sup>
</td>
<td>38 ± 13</td>
<td>.007</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>104 ± 22</td>
<td>118 ± 30</td>
<td>113 ± 32</td>
<td>115 ± 32</td>
<td>109 ± 24</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>27 ± 12</td>
<td>26 ± 10</td>
<td>28 ± 11</td>
<td>26 ± 10</td>
<td>27 ± 4</td>
<td>NS</td>
</tr>
<tr>
<td>Left atrium, mm</td>
<td>48 ± 8</td>
<td>45 ± 6<sup>g</sup>
</td>
<td>46 ± 7<sup>d</sup>
</td>
<td>47 ± 8</td>
<td>47 ± 8</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Right ventricle, mm</td>
<td>27 ± 4</td>
<td>26 ± 3</td>
<td>26 ± 3</td>
<td>27 ± 4</td>
<td>26 ± 3</td>
<td>NS</td>
</tr>
<tr>
<td>Pulmonary artery pressure</td>
<td>44 ± 15</td>
<td>40 ± 14<sup>a</sup>
</td>
<td>38 ± 13<sup>d</sup>
</td>
<td>40 ± 13</td>
<td>37 ± 4</td>
<td>.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319711436074">
<p>Abbreviations: ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; CAD, coronary artery disease; HDL, high-density lipoprotein; hs-CRP, high-sensitive C-reactive protein; LDL, Low-density lipoprotein.</p>
</fn>
<fn id="table-fn3-0003319711436074">
<p>
<sup>a</sup> <italic>P</italic> &lt; .05 statistically significant between patients without CAD and patients with CAD who had no revascularization procedure.</p>
</fn>
<fn id="table-fn4-0003319711436074">
<p>
<sup>b</sup> <italic>P</italic> &lt; .001 statistically significant between patients with CAD who had no revascularization procedure and patients with stent implantation.</p>
</fn>
<fn id="table-fn5-0003319711436074">
<p>
<sup>c</sup> <italic>P</italic> &lt; .05 statistically significant between patients with CAD who had no revascularization procedure and patients with stent implantation and CABG.</p>
</fn>
<fn id="table-fn6-0003319711436074">
<p>
<sup>d</sup> <italic>P</italic> &lt; .05 statistically significant between patients without CAD and patients with stent implantation.</p>
</fn>
<fn id="table-fn7-0003319711436074">
<p>
<sup>e</sup> <italic>P</italic> &lt; .05 statistically significant between patients without CAD and patients with stent implantation and CABG.</p>
</fn>
<fn id="table-fn8-0003319711436074">
<p>
<sup>f</sup> <italic>P</italic> &lt; .001 statistically significant between patients without CAD and patients with stent implantation.</p>
</fn>
<fn id="table-fn9-0003319711436074">
<p>
<sup>g</sup> <italic>P</italic> &lt; .001 statistically significant between patients without CAD and patients with CAD who had no revascularization procedure.</p>
</fn>
<fn id="table-fn10-0003319711436074">
<p>
<sup>h</sup> <italic>P</italic> &lt; .001 statistically significant between patients without CAD and patients with CABG.</p>
</fn>
<fn id="table-fn11-0003319711436074">
<p>
<sup>i</sup> <italic>P</italic> &lt; .001 statistically significant between patients without CAD and patients with stent implantation and CABG.</p>
</fn>
<fn id="table-fn12-0003319711436074">
<p>
<sup>j</sup> <italic>P</italic> &lt; .05 statistically significant between patients with CAD who had no revascularization procedure and patients with stent implantation.</p>
</fn>
<fn id="table-fn13-0003319711436074">
<p>
<sup>k</sup> <italic>P</italic> &lt; .05 statistically significant between patients without CAD and patients with CABG.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0003319711436074" position="float">
<label>Table 3.</label>
<caption>
<p>The Comparison Among the Patient Groups According to Their Etiology and the Treatments</p>
</caption>
<graphic alternate-form-of="table3-0003319711436074" xlink:href="10.1177_0003319711436074-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with stent implantation versus patients with CAD who had no revascularization procedure</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Patients with CABG surgery and stent implantation versus patients with CAD who had no revascularization procedure</td>
<td>.013</td>
</tr>
<tr>
<td>Patients without CAD versus patients with CAD had no revascularization procedure</td>
<td>.003</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-0003319711436074">
<p>Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Although patients with stent implantation had decreased cardiac death (hazard ratio [HR]: 0.521; 95% confidence interval [CI] 0.341-0.796, <italic>P</italic> = .039), the presence of CAD had increased cardiac death (HR, 1.437 [95% CI 1.081-1.911, <italic>P</italic> = .013]) in this study group.</p>
</sec>
<sec id="section10-0003319711436074">
<title>Discussion</title>
<p>In this study, the patients with CHF who were hospitalized due to decompansated HF were followed up for 38 ± 15 months after discharge from the hospital. Patients who had revascularization procedures as stent implantation and both stent implantation and CABG surgery in the past had better survival rate compared with the patients who had CAD without any coronary revascularization procedures. Although the patients with CABG surgery had better survival compared with patients with CAD without any revascularization procedure, the result did not reach statistical significance. It is interesting that stent implantation with or without CABG surgery in the patients with CAD and CHF had good impact on survival rate. We showed that the patients with CAD who could not have any revascularization procedures had worse outcomes than the patients without CAD.</p>
<p>The revascularization of patients with CAD who had left ventricular systolic dysfunction and CHF has been the subject of much debate over the last 30 to 40 years.<sup>
<xref ref-type="bibr" rid="bibr17-0003319711436074">17</xref>,<xref ref-type="bibr" rid="bibr18-0003319711436074">18</xref>
</sup> The current understanding of how best to treat these patients stems from subset analyses of the CABG and medicine clinical trials performed in the 1970s and early 1980s and analyses of large registries of patients from the same era.<sup>
<xref ref-type="bibr" rid="bibr19-0003319711436074">19</xref>,<xref ref-type="bibr" rid="bibr20-0003319711436074">20</xref>
</sup> Such analyses have generally demonstrated that patients with more advanced CAD and more severe left ventricular dysfunction derive more benefit from CABG relative to medical therapy.</p>
<p>The following have been hypothesized to underlie left ventricular systolic dysfunction in patients with CAD: (1) irreversible myocyte loss and replacement fibrosis after myocardial infarction (MI), and (2) hibernating myocardium which is viable but chronically dysfunctional with preserved integrity of the myocyte membrane and contractile fibers; these can resume function following revascularization.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711436074">21</xref>,<xref ref-type="bibr" rid="bibr22-0003319711436074">22</xref>
</sup> Transient contractile dysfunction “myocardial stunning” accompanies and follows episodes of ischemia during increases in myocardial metabolic demand in territories due to significant coronary stenoses and limited coronary flow reserve.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711436074">21</xref>,<xref ref-type="bibr" rid="bibr23-0003319711436074">23</xref>,<xref ref-type="bibr" rid="bibr24-0003319711436074">24</xref>
</sup>
</p>
<p>In this study, it seemed that both the revascularization procedures, CABG surgery and stent implantation, may have improved outcomes in the patients with CAD and CHF. Previous studies showed that CABG surgery and PCI may have good impact on survival in patients with CAD. Diabetic patients were recruited in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. The population of 2368 patients with stable CAD showed similar 5-year all-cause mortality rates in both the medical therapy and the revascularization by PCI or CABG groups. Only analysis of a secondary end point (composite of cardiac death and MI) revealed a benefit of CABG in patients with more extensive CAD compared with medical therapy or PCI; there were no differences between PCI and medical treatment.<sup>
<xref ref-type="bibr" rid="bibr25-0003319711436074">25</xref>,<xref ref-type="bibr" rid="bibr26-0003319711436074">26</xref>
</sup> On the other hand, the Swiss Interventional Study on Silent Ischemia Type II showed that in patients with recent MI, PCI reduced the long-term (10 years) risk of major cardiac events (composite of cardiac death, nonfatal MI, and/or symptom-driven revascularization) compared with optimal medical therapy in patients with silent ischemia demonstrated by stress imaging.<sup>
<xref ref-type="bibr" rid="bibr27-0003319711436074">27</xref>
</sup> A retrospective subgroup analysis of the randomized Coronary Artery Surgery Study trial suggested that patients with an LVEF of 35% to 50% had a mortality benefit from CABG in comparison with medical therapy at 10-year follow-up.<sup>
<xref ref-type="bibr" rid="bibr28-0003319711436074">28</xref>
</sup>
</p>
<p>In the Surgical Treatment for Ischemic Heart Failure (STICH) trial, the role of CABG was investigated in the treatment of patients with CAD and HF. It compared the strategy of medical therapy alone with that of medical therapy plus CABG in patients with CAD and left ventricular dysfunction. Randomization of the patients with HF, LVEF of 0.35 or less, and CAD is based on whether patients are judged by attending physicians to be candidates only for CABG surgery or can be treated with medical therapy without CABG. Patients who were eligible for all 3 therapy arms were randomly assigned to medical therapy only, medical therapy and CABG surgery, or medical therapy and CABG surgery, and surgical ventricular reconstruction. There was no significant difference between the 2 study groups with respect to the primary end point of the rate of death from any cause. The rates of death by cardiovascular causes and of death from any cause or hospitalization for cardiac causes were lower among patients assigned to CABG than among those assigned to medical therapy.<sup>
<xref ref-type="bibr" rid="bibr29-0003319711436074">29</xref>
</sup> In STICH, the patients with previous PCI were included equally in both arms and PCI was considered as part of the medical stratum. It was also observed in another study that in patients with HF and CAD, a prior CABG surgery was associated with a significant reduction in all-cause mortality.<sup>
<xref ref-type="bibr" rid="bibr30-0003319711436074">30</xref>
</sup>
</p>
<p>Pocar et al retrospectively analyzed 45 consecutive angina-free patients with ischemic left ventricular dysfunction (ejection fraction &lt;0.35) and HF (New York Heart Association [NYHA] classes III-IV) who were selected for CABG between 1988 and 1995. Positron emission tomography was used for preoperative identification of myocardial viability. The 30-day mortality was 4.4%. At a median follow-up of 117 months, the probability of survival at 1, 5, 10, and 15 years after CABG was 93.3%, 84%, 65%, and 44%, respectively. Cardiac events accounted for 88% of late deaths, which were primarily related to sudden death or progressive HF. This retrospective study showed that CABG alone yields good long-term outcome in selected angina-free patients with ischemic systolic dysfunction and advanced HF.<sup>
<xref ref-type="bibr" rid="bibr31-0003319711436074">31</xref>
</sup>
</p>
<p>The SYNTAX trial<sup>
<xref ref-type="bibr" rid="bibr32-0003319711436074">32</xref>
</sup> compared PCI and CABG for treating patients with previously untreated 3-vessel or left main CAD (or both). A higher proportion of patients had complete revascularization after CABG than after PCI (63.2% vs 56.7%; <italic>P</italic> = .005). It has been demonstrated by Serruys et al<sup>
<xref ref-type="bibr" rid="bibr32-0003319711436074">32</xref>
</sup> that the rates of major adverse cardiac or cerebrovascular events at 12 months were significantly higher in the PCI group (17.8% vs 12.4% for CABG; <italic>P</italic> = .002) in large part because of an increased rate of repeat revascularization (13.5% vs 5.9%; <italic>P</italic> &lt; .001). The rates of death and myocardial infarction were similar between the 2 groups; stroke was significantly more likely to occur with CABG (2.2% vs 0.6% with PCI; <italic>P</italic> = .003) at 12 months. The authors concluded that CABG remains the standard of care for patients with 3-vessel or left main coronary artery disease since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year.</p>
<p>Biondi Zoccai et al<sup>
<xref ref-type="bibr" rid="bibr33-0003319711436074">33</xref>
</sup> tried to assess the effect of PCI in patients with left ventricular dysfunction on clinical outcomes. They performed a systematic review of studies reporting on PCI in left ventricular dysfunction. The studies included reported on ≥30 patients, with ejection fraction &lt;50%, and prevalently (&gt;60%) treated with stents. The primary end point was the occurrence of major adverse cardiovascular events (MACEs) at the longest follow-up. They retrieved 11 studies including 1284 patients with ejection fraction &lt;50% (specifically &lt;40% in 1033 and &lt;30% in 211).<sup>
<xref ref-type="bibr" rid="bibr33-0003319711436074">33</xref>
</sup> In-hospital MACE occurred in 5%, with death in 2%, MI in 3%, and repeat revascularization in 1%. After a median of 18 months, MACE occurred in 33%, with death in 11%, MI in 7%, and repeat revascularization in 15%. Meta-regression suggested the beneficial impact of drug-eluting stents on MACE (<italic>P</italic> = .030). They conclude that the available data support the adoption of percutaneous revascularization in carefully selected patients with left ventricular systolic dysfunction. While event attrition remains substantial at long-term follow-up, drug-eluting stents hold the promise of significantly improving event-free and overall survival.<sup>
<xref ref-type="bibr" rid="bibr33-0003319711436074">33</xref>
</sup> We showed that the patients who had poor left ventricular systolic function and stent implantation in their past had better outcome compared to patients without coronary revascularization procedures.</p>
</sec>
<sec id="section11-0003319711436074">
<title>Conclusions</title>
<p>Our study supported the studies which reported that the revascularization procedures had better effect on the prognosis in CHF compared to medical treatment alone. It was also determined that the patients with CAD but no revascularization in the past had the worse prognosis compared to the patients with nonischemic HF and the patients with revascularization such as stent implantation, and both stent implantation and CABG in the patients with CHF. As a clinician, our mission is that we should identify the patients who benefit from coronary revascularization to ensure the best outcome.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711436074">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711436074">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711436074">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Is detection of hibernating myocardium necessary in deciding revascularization in systolic heart failure?</article-title> <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>(<issue>2</issue>):<fpage>236</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711436074">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Mujib</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>RV</given-names>
</name>
<etal/>
</person-group>. <article-title>Outcomes in younger and older adults with chronic advanced systolic heart failure: a propensity-matched study</article-title>. <source>Int J Cardiol</source>. <year>2010</year>:<volume>144</volume>(<issue>3</issue>):<fpage>383</fpage>–<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711436074">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottdiener</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Aurigemma</surname>
<given-names>GP</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors of congestive heart failure in the elderly: the cardiovascular Health Study</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>35</volume>(<issue>6</issue>):<fpage>1628</fpage>–<lpage>1637</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711436074">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sopko</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Navigating the crossroads of coronary artery disease and heart failure</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>11</issue>):<fpage>1202</fpage>–<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711436074">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with theAmerican College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>:<issue>(12)</issue>:<fpage>e154</fpage>–<lpage>e235</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711436074">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flaherty</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute heart failure syndromes in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>(<issue>3</issue>):<fpage>254</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711436074">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bart</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>McCants</surname>
<given-names>Jr CB</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical determinants of mortality inpatients with angiographically diagnosed ischemic or nonischemic cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source>. <year>1997</year>;<volume>30</volume>(<issue>4</issue>):<fpage>1002</fpage>–<lpage>1008</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711436074">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felker</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>342</volume>(<issue>15</issue>):<fpage>1077</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711436074">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westaby</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Coronary revascularization in ischemic cardiomyopathy</article-title>. <source>Surg Clin North Am</source>. <year>2004</year>;<volume>84</volume>(<issue>1</issue>):<fpage>179</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711436074">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Cowley</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wolfgang</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Vetrovec</surname>
<given-names>GW</given-names>
</name>
</person-group>. <article-title>Acute changes in global and regional rest ventricular function after successful coronary angioplasty: comparative results in stable and unstable angina</article-title>. <source>J Am Coll Cardiol</source>. <year>1989</year>;<volume>13</volume>(<issue>6</issue>):<fpage>1262</fpage>–<lpage>1269</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711436074">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>K</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McGlothlin</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Remodeling in systolic heart failure—effects of neurohormonal modulators—basis for current pharmacotherapy</article-title>. <source>Cardiol Today</source>. <year>2005</year>;<volume>9</volume>:<fpage>270</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711436074">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brower</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Fioretti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Simoons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haalebos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rulf</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Hugenholtz</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Surgical versus non-surgical management of patients soon after acute myocardial infarction</article-title>. <source>Br Heart J</source>. <year>1985</year>;<volume>54</volume>(<issue>5</issue>):<fpage>460</fpage>–<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711436074">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iwase</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishiwata</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of long-term efficacy of medical treatment versus coronary artery bypass grafting (CABG) in multivessel coronary artery disease</article-title>. <source>Jpn Heart J</source>. <year>1995</year>;<volume>36</volume>(<issue>6</issue>):<fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711436074">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treasure</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Coronary artery bypass surgery</article-title>. <source>Br J Hosp Med</source>. <year>1983</year>;<volume>30</volume>(<issue>4</issue>):<fpage>259</fpage>–<lpage>60</lpage>, <fpage>262</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711436074">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy of coronary angioplasty on long-term outcome in elderly Chinese patients with ST elevated myocardial infarction</article-title>. <source>Cell Biochem Biophys</source>. <year>2010</year>;<volume>57</volume>(<issue>2-3</issue>):<fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711436074">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahn</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>DeMaria</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kisslo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weyman</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements</article-title>. <source>Circulation</source>. <year>1978</year>;<volume>58</volume>(<issue>6</issue>):<fpage>1072</fpage>–<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711436074">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charaeonthaitawee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gersh</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Araoz</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Revascularization in severe left ventricular dysfunction: the role of viability testing</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>4</issue>):<fpage>567</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711436074">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Is it time for a randomized trial of surgical treatment of ischemic heart failure?</article-title> <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>37</volume>(<issue>5</issue>):<fpage>1210</fpage>–<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711436074">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passamani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Killip</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>A randomized trial of coronary artery bypass surgery. Survival in patients with a low ejection fraction</article-title>. <source>N Engl J Med</source>. <year>1985</year>;<volume>312</volume>(<issue>26</issue>):<fpage>1665</fpage>–<lpage>1671</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711436074">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Connor</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Velazquez</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>LH</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank)</article-title>. <source>Am J Cardiol</source>. <year>2002</year>;<volume>90</volume>(<issue>2</issue>):<fpage>101</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711436074">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camici</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Rimoldi</surname>
<given-names>OE</given-names>
</name>
</person-group>. <article-title>Stunning, hibernation, and assessment of myocardial viability</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711436074">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ammirati</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rimoldi</surname>
<given-names>OE</given-names>
</name>
<name>
<surname>Camici</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Is there evidence supporting coronary revascularization in patients with left ventricular systolic dysfunction?</article-title> <source>Circ J</source>. <year>2010</year>;<volume>75</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711436074">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijns</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Vatner</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Camici</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Hibernating myocardium</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>(<issue>3</issue>):<fpage>173</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711436074">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uren</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>De Bruyne</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wijns</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Baudhuin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Camici</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Relation between myocardial blood flow and the severity of coronary-artery stenosis</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>330</volume>(<issue>25</issue>):<fpage>1782</fpage>–<lpage>1788</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711436074">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>August</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized trial of therapies for type 2 diabetes and coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>24</issue>):<fpage>2503</fpage>–<lpage>2515</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711436074">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Hardison</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>(<issue>25</issue>):<fpage>2529</fpage>–<lpage>2540</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711436074">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schoenenberger</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Burckhardt</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>297</volume>(<issue>18</issue>):<fpage>1985</fpage>–<lpage>1991</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711436074">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alderman</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Bourassa</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>LS</given-names>
</name>
<etal/>
</person-group>. <article-title>Ten-year follow-up of survival and myocardial infarction in the randomized coronary artery surgery study</article-title>. <source>Circulation</source>. <year>1990</year>;<volume>82</volume>(<issue>5</issue>):<fpage>1629</fpage>–<lpage>1646</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711436074">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velazquez</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Deja</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>; <article-title>STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>17</issue>):<fpage>1607</fpage>–<lpage>1616</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711436074">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Flaherty</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</name>
<etal/>
</person-group>. <article-title>Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure</article-title>. <source>Int J Cardiol</source>. <year>2011</year>;<volume>151</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711436074">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pocar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moneta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Donatelli</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Coronary artery bypass for heart failure in ischemic cardiomyopathy: 17-year follow-up</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>(<issue>2</issue>):<fpage>468</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711436074">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serruys</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Morice</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kappetein</surname>
<given-names>AP</given-names>
</name>
<etal/>
</person-group>; <article-title>SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>10</issue>):<fpage>961</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711436074">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondi Zoccai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Abbate</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Percutaneous coronary stenting in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis</article-title>. <source>EuroIntervention</source>. <year>2007</year>;<volume>3</volume>(<issue>3</issue>):<fpage>409</fpage>–<lpage>415</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>